International Urogynecology Journal

, Volume 8, Issue 5, pp 293–295

Pentosanpolysulphate for interstitial cystitis

  • J. W. Barrington
  • T. P. Stephenson
Review Article

DOI: 10.1007/BF02765487

Cite this article as:
Barrington, J.W. & Stephenson, T.P. Int Urogynecol J (1997) 8: 293. doi:10.1007/BF02765487

Abstract

Interstitial Cystitis (IC) is a chronic disease of unknown etiology which primarily affects women aged 40–60 years. Many plausible theories for the development of IC have been postulated, and one current theory is that these patients have a quantitative and qualitative defect in the glycosaminoglycan (GAG) layer of the urothelium. Such a defect may allow toxic substances in the urine to gain access to the lamina propria and initiate a chronic inflammatory process. Pentosanpolysulphate (PPS) is a sulphated proteoglycan similar in structure to heparin sulphate, which is quantitatively the major GAG on cell surfaces. Exogenously administered PPS has been shown in several studies to decrease bladder pain and urinary frequency and to increase the voided volume. Further studies are required to evaluate the role of PPS in the management of IC patients, with particular emphasis on dosage, route of administration and combination with other compounds.

Keywords

Defective GAG layer Interstitial cystitis Pentosanpolysulphate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag London Ltd 1997

Authors and Affiliations

  • J. W. Barrington
    • 1
  • T. P. Stephenson
    • 2
  1. 1.Department of Obstetrics and GynaecologyTorbay, HospitalTorquayUK
  2. 2.Department of UrologyUniversity Hospital of WalesCardiffUK

Personalised recommendations